H.C. Wainwright Reiterates Buy Rating on Cardiff Oncology (CRDF)

March 26, 2026 6:49 AM

H.C. Wainwright analyst Raghuram Selvaraju reiterated a Buy rating and $10.00 price target on Cardiff Oncology (NASDAQ: CRDF).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found